Advance Purchase Agreement

The company`s platform builds on continuous advances in the fundamental and applied science of RNA, delivery technology and manufacturing and offers Moderna the opportunity to pursue a robust pipeline of new development candidates in parallel. Moderna develops with strategic partners therapeutic drugs and vaccines for infectious diseases, immunoncology, rare diseases and cardiovascular diseases. The Australian government has entered into a number of pre-emption contracts to ensure australians will have access to COVID-19 vaccines as soon as they have proven their safety and efficacy. European Commission`s option to purchase up to 80 million additional doses Moderna announces the European Commission`s approval of the pre-purchase contract for 80 million initial doses of COVID-19 RNA vaccine An Advance Pricing Agreement (APA) is a prior agreement between a taxable person and a tax authority on an appropriate transfer pricing method (TPM) for a series of transactions, that are relevant over a period of time[1] (so-called “hedged” transactions). This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including the terms of the Company`s planned sale of mRNA-1273 to the European Commission and European Union Member States; the intended conclusion of the agreement for such a sale; the date of delivery of the mRNA-1273 to the European Commission; plans to submit to the EMA a single application for authorisation of mRNA-1273; the potential for the commercialization of mRNA-1273 in EU Member States and other countries; the effectiveness of mRNA-1273 and its ability to prevent infections or alleviate symptoms of COVID-19; and plans for the production of mRNA-1273 and the expected scale of production…

Posted in Uncategorized